ArticleBMC ophthalmology2026
Comparable myopia control efficacy of highly aspherical lenslets and diffusion optics technology spectacle lenses: a one-year real-world cohort study.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo compare the real-world efficacy of Highly Aspherical Lenslets (HAL) spectacles, Diffusion Optics Technology (DOT) spectacles, and single vision lenses (SVL) for controlling myopia progression in children and adolescents.
methodsA total of 159 participants aged 6 to 13 years were enrolled from the Ophthalmology Clinic of Nanjing Children's Hospital between April 2024 and September 2025, comprising 53 subjects each in the HAL, DOT, and SVL groups. Participants were further stratified into a younger subgroup (6 to < 10 years) and an older subgroup (10 to13 years). One-way analysis of variance was used to compare changes in spherical equivalent (SE) and axial length(AL) after one year.
resultsBoth HAL and DOT groups were associated with significantly slower progression in SE and AL than the SVL group (all P < 0.001), with no statistically significant differences between the two treatment groups (P = 0.35 for SE; P = 0.22 for AL). In both age subgroups, axial elongation was similar between HAL and DOT (P = 0.52 and P = 0.15), and both were significantly slower than SVL in the older subgroup (both P < 0.001). In the younger subgroup, HAL also slowed axial elongation significantly compared with SVL (P = 0.003), whereas the difference between DOT and SVL did not reach statistical significance after Bonferroni correction (P = 0.02), although the observed absolute difference of 0.11 mm per year may still be clinically meaningful. Pearson correlation analysis showed that only age was significantly correlated with AL elongation in both the HAL (r= - 0.35, P = 0.024) and DOT groups (r= - 0.48, P = 0.001).
conclusionIn this real-world cohort, both HAL and DOT lenses were linked to slower myopia progression, with similar progression rates between HAL and DOT. However, the efficacy of DOT in younger children (aged 6 to < 10 years) requires further investigation with larger sample sizes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.